PP_1170x120_10-25-21

CureVac N.V

GSK and CureVac to develop next generation mRNA COVID-19 vaccines

GSK and CureVac to develop next generation mRNA COVID-19 vaccines

NEW YORK— GlaxoSmithKline and CureVac N.V have announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine. GSK will also support the manufacture of up to 100 million doses of CureVac’s